The 10th Annual Future of the Pharmaceutical Benefits Scheme Summit

The 10th Annual
Future of the Pharmaceutical Benefits Scheme Summit
29th & 30th April 2013 Sydney Harbour Marriot Hotel

TOWARDS IMPROVING THE EFFECTIVENESS OF THE PBS, ECONOMIC EFFICIENCY AND SUSTAINABILITY

The 10th Annual Future of the Pharmaceutical Benefits Scheme will address by leading experts, the latest views on improving the effectiveness, economic efficiency and sustainability of the scheme and invite federal and opposition to address this subject.

This summit will explore a variety of challenges facing government, manufacturers, retailers, pharmacists and associations in relations to the future of the PBS.

KEY CONFERENCE TOPICS INCLUDE:

• Labelling of PBS Medicines
• Prescribing on the PBS by other health professionals
• Access to pharmacy services
• Balancing government funding and co-payments to gain most value and economic efficiency
• Chemotherapy Supply Sustainability - the long and winding road
• Overview of the Minor Ailments Scheme
• Dispute resolution process - What that means and how it works?
• Changing the medications funded by the PBS
• Biosimilars
• Challenges with price discloser

OUTSTANDING FACULTY OF SPEAKERS INCLUDES:

• Mark Fladrich, Managing Director, AstraZeneca Australia & New Zealand
• Elizabeth De Somer, Director, Health Policy & Research, Medicines Australia
• Dr. Paul Gross, Director, Institute of Health Economics and Technology Assessment, and Director, Health Group Strategies Australia and Greater China
• Greg Johnson, CEO, Diabetes Australia
• Kos Sclavos, National President, Pharmacy Guild of Australia
• Pattie Beerens, CEO, National Pharmaceutical Services Association (NPSA)
• Kate Lynch, CEO, Generic Medicines industry Association (GMiA)
• Darryl Grundy, Chief Executive Officer, UQ Healthcare
• Lisa Briggs, CEO, National Aboriginal Community Controlled Health Organisation (NACCHO)
• Greg Johnson, Chief Executive Officer, Diabetes Australia